Clinical Impact of BTK Inhibitor Exposure in LymphGen‐Defined MCD Diffuse Large B‐Cell Lymphoma
Hematological Oncology · 2026
DOI: 10.1002/hon.70224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Shiyu Jiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Clinical Research Special Project of Shanghai Municipal Health Commission, Chinese Society of Clinical Oncology Chaoyang Oncology Research Fund Project.
Abstract (Originalsprache)
The molecular subtype characterized by co‐occurring MYD88 and CD79B alterations (MCD) represents a biologically distinct subset of diffuse large B‐cell lymphoma (DLBCL) with chronic active B‐cell receptor signaling and a high risk of central nervous system (CNS) involvement. The clinical impact of Bruton tyrosine kinase inhibitors (BTKi) in this subtype remains unclear. We retrospectively analyzed 155 patients with newly diagnosed DLBCL harboring genetic features consistent with the MCD subtype. At a median follow‐up of 34.1 months, the estimated 3‐year progression‐free survival (PFS) rate was 76.1%. BTKi exposure ( n = 56) was associated with significantly improved PFS compared with no BTKi exposure (3‐year PFS: 93.8% vs. 66.6%, p < 0.001) and remained independently associated with improved PFS after adjustment for IPI risk (HR 0.16, p < 0.001). Overall survival did not differ significantly between groups. Notably, all 15 CNS relapse events occurred in patients who did not receive BTKi, whereas no CNS relapse was observed in the BTKi‐treated group. BTKi exposure was independently associated with a markedly reduced risk of CNS relapse (HR 0.06, p = 0.002) after adjustment for CNS‐IPI risk and CNS prophylaxis. These findings suggest that BTK inhibition may improve outcomes and mitigate CNS relapse in MCD DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
ORCID-Profile: Xiaojian Liu
Förderung
- National Natural Science Foundation of China
- Clinical Research Special Project of Shanghai Municipal Health Commission
- Chinese Society of Clinical Oncology Chaoyang Oncology Research Fund Project
- Innovation Program of Shanghai Science and Technology Committee
- Clinical Research Plan of Shanghai Hospital Development Center
Zitieren
APA
Jiang, S., Liu, Y., Wei, R., Zhang, W., Bao, L., Jin, J., Lv, F., Liu, C., Liu, X., Sun, H., Wang, J., Tao, R., Cao, J., Zhou, X., & Zhang, Q. (2026). Clinical Impact of BTK Inhibitor Exposure in LymphGen‐Defined MCD Diffuse Large B‐Cell Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70224
Vancouver
Jiang S, Liu Y, Wei R, Zhang W, Bao L, Jin J, et al. Clinical Impact of BTK Inhibitor Exposure in LymphGen‐Defined MCD Diffuse Large B‐Cell Lymphoma. Hematological Oncology. 2026. doi:10.1002/hon.70224
BibTeX
@article{Jiang2026,
author = {Jiang, Shiyu and Liu, Yizhen and Wei, Ran and Zhang, Wenhao and Bao, Longlong and Jin, Jia and Lv, Fangfang and Liu, Chuanxu and Liu, Xiaojian and Sun, Hui and Wang, Jiachen and Tao, Rong and Cao, Junning and Zhou, Xiaoyan and Zhang, Qunling},
title = {Clinical Impact of BTK Inhibitor Exposure in LymphGen‐Defined MCD Diffuse Large B‐Cell Lymphoma},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70224}
}
EUVIMED